Mode
Text Size
Log in / Sign up
Phase 4 Completed N=366 Diagnostic

A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease

Source: ClinicalTrials.gov NCT00162370 ↗
Enrolled (actual)
366
Serious AEs
0.0%
Results posted
Dec 2016
Primary outcomePrimary: Number of Participants With Abnormal Contrast Stress Echocardiography and With Future Major Adverse Cardiac Events (MACE) at 2 and 5 Years Follow-Up — 2; 1; 1; 5 Participants — p=0.014
◆ Published Evidence
Emerging
11citations · ~1 / year
Prognostic Utility of Stress Testing and Cardiac Biomarkers in Menopausal Women at Low to Intermediate Risk for Coronary ARTery Disease (SMART Study): 5-Year Outcome.
Journal of women's health (2002) · 2018 · Likely link

Summary

The study is designed to see if stress echocardiography can be used as a screening exam in peri-, or post-menopausal women with a risk of developing of coronary artery disease and experiencing future cardiac events.

Linked Publications (2)

  • Prognostic Utility of Stress Testing and Cardiac Biomarkers in Menopausal Women at Low to Intermediate Risk for Coronary ARTery Disease (SMART Study): 5-Year Outcome.
    Journal of women's health (2002) · 2018 · 11 citations · Likely link
  • Effect of stress echocardiography testing on changes in cardiovascular risk behaviors in postmenopausal women: a prospective survey study.
    Journal of women's health (2002) · 2014 · 1 citation · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Abnormal Contrast Stress Echocardiography and With Future Major Adverse Cardiac Events (MACE) at 2 and 5 Years Follow-Up
2; 1; 1; 5 0.014 sig
SECONDARY
Number of Participants With Abnormal ECG and With Major Adverse Cardiac Events (MACE) at 2 Year Follow-Up
3; 15 <0.0001 sig
SECONDARY
Change in Brain Natriuretic Peptide (BNP) in Subjects With and Without Major Adverse Cardiac Events at 2-year Follow-up.
5.2; 10.7
SECONDARY
Change in Atrial Natriuretic Peptide (ANP) in Subjects With and Without Major Adverse Cardiac Events at 2-year Follow-up.
5.9; 101
SECONDARY
Change in Brachial Artery Reactivity Was Assessed in in a Subset of Participants With and Without Major Adverse Cardiac Events at 2-year and 5-year Follow-up.
7.8; 7.3
SECONDARY
Mean Baseline Calcium Score of Participants With and Without Major Cardiac Events at 2-year Follow up.
45
SECONDARY
The Presence of Wall Motion Abnormalities on Definity Stress Echocardiography Assessed for Participants With Both Normal and Abnormal Angiography
7; 12; 1; 4
SECONDARY
Participants With Positive and Negative Angiography Compared With Their ECG Results
15; 4; 3; 2
SECONDARY
Number of Participants With Abnormal ECG and With Future Major Adverse Cardiac Events (MACE) at 5 Years Follow-Up
16.7; 5.0
SECONDARY
Change in Brain Natriuretic Peptide (BNP) in Participants With and Without Major Adverse Cardiac Events at 5-year Follow-up.
4.9; 4.1
SECONDARY
Change in Atrial Natriuretic Peptide (ANP) in Participants With and Without Major Adverse Cardiac Events at 5-year Follow-up.
-37.4; 70.5
SECONDARY
Mean Calcium Score of Participants With and Without Major Cardiac Events at 5-year Follow up.
40.2; 100

Eligibility Criteria

Inclusion Criteria

  • Peri or Post menopausal women either:
  • without symptoms but with risk factors for heart disease OR
  • experiencing atypical chest pain, OR
  • experiencing exertional dyspnea AND 2 or more risk factors for CAD
  • Must be able to perform an exercise stress test

Peri-or post-menopausal (including surgical menopause) based on history.

  • Post-menopausal is defined as females age 40-65 who self-report the absence of menstrual periods for at least 12 months.
  • Peri-menopausal is defined as females age 40-65 who self-report the absence or irregularity of menstrual periods for 6-12 months.
  • Surgical menopause is defined as females who have had a bilateral salpingo-oophorectomy with or without hysterectomy.

Exclusion Criteria

  • Previous confirmed heart disease
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00162370) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search